JUN promotes hypertrophic skin scarring via CD36 in preclinical in vitro and in vivo models.

Return to Grants

Publication Year:
2021
Authors:
Michelle F Griffin, Mimi R Borrelli, Julia T Garcia, Michael Januszyk, Megan King, Tristan Lerbs, Lu Cui, Alessandra L Moore, Abra H Shen, Shamik Mascharak, Nestor M Diaz Deleon, Sandeep Adem, Walter L Taylor, Heather E desJardins-Park, Marc Gastou, Ronak A Patel, Bryan A Duoto, Jan Sokol, Yuning Wei, Deshka Foster, Kellen Chen, Derrick C Wan, Geoffrey C Gurtner, Hermann P Lorenz, Howard Y Chang, Gerlinde Wernig, Michael T Longaker
PubMed ID:
34516825
Funding Grants:
Public Summary:
Pathologic skin scarring presents a vast economic and medical burden. Unfortunately, the molecular mechanisms underlying scar formation remain to be elucidated. We used a hypertrophic scarring (HTS) mouse model in which Jun is overexpressed globally or specifically in alpha-smooth muscle or collagen type I-expressing cells to cause excessive extracellular matrix deposition by skin fibroblasts in the skin after wounding. Jun overexpression triggered dermal fibrosis by modulating distinct fibroblast subpopulations within the wound, enhancing reticular fibroblast numbers, and decreasing lipofibroblasts. Analysis of human scars further revealed that JUN is highly expressed across the wide spectrum of scars, including HTS and keloids. CRISPR-Cas9-mediated JUN deletion in human HTS fibroblasts combined with epigenomic and transcriptomic analysis of both human and mouse HTS fibroblasts revealed that JUN initiates fibrosis by regulating CD36. Blocking CD36 with salvianolic acid B or CD36 knockout model counteracted JUN-mediated fibrosis efficacy in both human fibroblasts and mouse wounds. In summary, JUN is a critical regulator of pathological skin scarring, and targeting its downstream effector CD36 may represent a therapeutic strategy against scarring.
Scientific Abstract:
Pathologic skin scarring presents a vast economic and medical burden. Unfortunately, the molecular mechanisms underlying scar formation remain to be elucidated. We used a hypertrophic scarring (HTS) mouse model in which Jun is overexpressed globally or specifically in alpha-smooth muscle or collagen type I-expressing cells to cause excessive extracellular matrix deposition by skin fibroblasts in the skin after wounding. Jun overexpression triggered dermal fibrosis by modulating distinct fibroblast subpopulations within the wound, enhancing reticular fibroblast numbers, and decreasing lipofibroblasts. Analysis of human scars further revealed that JUN is highly expressed across the wide spectrum of scars, including HTS and keloids. CRISPR-Cas9-mediated JUN deletion in human HTS fibroblasts combined with epigenomic and transcriptomic analysis of both human and mouse HTS fibroblasts revealed that JUN initiates fibrosis by regulating CD36. Blocking CD36 with salvianolic acid B or CD36 knockout model counteracted JUN-mediated fibrosis efficacy in both human fibroblasts and mouse wounds. In summary, JUN is a critical regulator of pathological skin scarring, and targeting its downstream effector CD36 may represent a therapeutic strategy against scarring.